- Home
- BMBL vs MREO Comparison
BMBL vs MREO Comparison
Compare BMBL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- MREO
- Stock Information
- Founded
- BMBL 2014
- MREO 2015
- Country
- BMBL United States
- MREO United Kingdom
- Employees
- BMBL N/A
- MREO N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- MREO Health Care
- Exchange
- BMBL Nasdaq
- MREO Nasdaq
- Market Cap
- BMBL 446.5M
- MREO 424.5M
- IPO Year
- BMBL 2021
- MREO N/A
- Fundamental
- Price
- BMBL $5.74
- MREO $2.55
- Analyst Decision
- BMBL Hold
- MREO Strong Buy
- Analyst Count
- BMBL 15
- MREO 7
- Target Price
- BMBL $6.56
- MREO $7.71
- AVG Volume (30 Days)
- BMBL 3.5M
- MREO 929.0K
- Earning Date
- BMBL 05-07-2025
- MREO 05-13-2025
- Dividend Yield
- BMBL N/A
- MREO N/A
- EPS Growth
- BMBL N/A
- MREO N/A
- EPS
- BMBL N/A
- MREO N/A
- Revenue
- BMBL $1,050,969,000.00
- MREO N/A
- Revenue This Year
- BMBL N/A
- MREO N/A
- Revenue Next Year
- BMBL N/A
- MREO $54.91
- P/E Ratio
- BMBL N/A
- MREO N/A
- Revenue Growth
- BMBL N/A
- MREO N/A
- 52 Week Low
- BMBL $3.55
- MREO $1.58
- 52 Week High
- BMBL $12.03
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- BMBL 57.60
- MREO 60.30
- Support Level
- BMBL $5.67
- MREO $2.11
- Resistance Level
- BMBL $6.26
- MREO $2.27
- Average True Range (ATR)
- BMBL 0.25
- MREO 0.15
- MACD
- BMBL -0.03
- MREO 0.01
- Stochastic Oscillator
- BMBL 25.71
- MREO 98.88
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).